Vepdegestrant Results in Longer PFS Than Fulvestrant in Previously Treated Patients with ESR1-mutated, ER-positive, HER2-negative ABC By Ogkologos - June 4, 2025 514 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the VERITAC-2 study Source RELATED ARTICLESMORE FROM AUTHOR The Legacy of the ESMO Patient Engagement Summit 2025: Advancing Rights of Patients with Cancer via Cross-Border Best Practices and Collaboration Sustained PFS Benefit of Imlunestrant Over SoC in Patients with ESR1-mutated Advanced Breast Cancer ESMO Welcomes Launch of Health Package Introducing EU Measures That Can Boost Innovation in Oncology and Help Prevent New Cancer Cases MOST POPULAR Wishes for a New Year! December 31, 2021 Five Questions with…Fred. April 14, 2022 Managing Cancer Pain: Are Better Approaches on the Horizon? January 23, 2019 Thinking outside the box to tackle an aggressive children’s cancer September 8, 2021 Load more HOT NEWS Lorlatinib in First-Line Treatment of Patients with Advanced ALK-Positive NSCLC With... ESMO Congress 2022, 9-13 September Darolutamide Extends Survival for Some People with Metastatic Prostate Cancer Race for Life events are back this autumn
